Last reviewed · How we verify
NCT06784167
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
trial testing Non-Interventional Study in Chronic Lymphocytic Leukemia in 45 participants. Currently enrolling.
11 January 2027
Quick facts
| Lead sponsor | OHSU Knight Cancer Institute |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 45 |
| Start date | 10 March 2025 |
| Primary completion | 11 January 2027 |
| Estimated completion | 12 April 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Non-Interventional Study (non-interventional-study) — full drug profile →
Conditions studied
- Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →
- Diffuse Large B-Cell Lymphoma — all drugs for Diffuse Large B-Cell Lymphoma →
- Follicular Lymphoma — all drugs for Follicular Lymphoma →
- Mantle Cell Lymphoma — all drugs for Mantle Cell Lymphoma →
Sponsor
OHSU Knight Cancer Institute
Who can join
18 and older, any sex, with Chronic Lymphocytic Leukemia or Diffuse Large B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06784167
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Non-Interventional Study
Trials testing the same drug.
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
- NCT06607874 — Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in · not yet recruiting
- NCT06630338 — Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements · not yet recruiting
- NCT07235501 — Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hemato · not yet recruiting
Other recruiting trials for Chronic Lymphocytic Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
- NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
- NCT07288515 — Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus · recruiting
- NCT07014917 — Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL · Phase 2 · recruiting
Other OHSU Knight Cancer Institute trials
Trials by the same sponsor.
- NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
- NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
- NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
- NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06784167 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
- Last refreshed: 15 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06784167.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing